Comparison of six cannabinoid metabolite assays.
Numerous methods for the detection of urinary metabolites of marijuana constituents are available. Documentation of the sensitivity and specificity of these tests is needed before the determination of a pair of screening-confirmation tests can be made. This study used 88 clinical specimens to evaluate five commercially available marijuana metabolite methods and one new gas chromatography/mass spectrometry (GC/MS) method. The EMIT-d.a.u. test was found to have 2 to 3% unconfirmed positives when compared to the other methods evaluated. The new thin layer procedure, TOXI-LAB, was not as sensitive as the EMIT-d.a.u. procedure for some specimens, but proved to be a good confirmation for the EMIT-d.a.u. with elimination of all "unconfirmed positives." The Abuscreen (Roche) and the EMIT-st assays were positive for samples that contained larger amounts of 11-nor-delta 9-tetrahydrocannabinol-9-carboxylic acid (11-nor-delta 9-THC-9-COOH). The Immunalysis-radioimmunoassay (RIA) was positive for all samples found positive by the GC/MS method, but the concentrations found by the two assays did not correlate. The GC/MS method was developed to use the same extraction as the thin layer procedure and provides confirmation for all procedures except 2 to 3% of the positive EMIT-d.a.u. results.
D002186:Cannabinoids / Q000652:urine*; D002188:Cannabis / Q000032:analysis; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D007124:Immunoenzyme Techniques; D007457:Iodine Radioisotopes
D002186:Cannabinoids; D007457:Iodine Radioisotopes